The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Naringin is a Major and Selective Clinical Inhibitor of Organic Anion-Transporting Polypeptide 1A2 (OATP1A2) in Grapefruit Juice
Abstract
We showed previously that grapefruit and orange juices inhibited human enteric organic anion-transporting polypeptide (OATP)1A2 in vitro and lowered oral fexofenadine bioavailability clinically. Inhibition of OATP1A2 transport by flavonoids in grapefruit (naringin) and orange (hesperidin) was conducted in vitro. Two randomized, crossover, pharmacokinetic studies were performed clinically. In one study, 120 mg of fexofenadine was ingested with 300 ml grapefruit juice, an aqueous solution of naringin at the same juice concentration (1,200 microM), or water. In the other study, fexofenadine was administered with grapefruit juice, with or 2 h before aqueous suspension of the particulate fraction of juice containing known clinical inhibitors of enteric CYP3A4, but relatively low naringin concentration (34 microM), or with water. Naringin and hesperidin's half-maximal inhibitions were 3.6 and 2.7 microM, respectively. Fexofenadine area under the plasma drug concentration-time curves (AUCs) with grapefruit juice and naringin solution were 55% (P<0.001) and 75% (P<0.05) of that with water, respectively. Fexofenadine AUCs with grapefruit juice and particulate fractions were 57% (P<0.001), 96% (not significant (NS)), and 97% (NS) of that with water, respectively. Individuals tested in both studies (n=9 of 12) had highly reproducible fexofenadine AUC with water (r(2)=0.85, P<0.001) and extent of reduction of it with grapefruit juice (r(2)=0.72, P<0.01). Naringin most probably directly inhibited enteric OATP1A2 to decrease oral fexofenadine bioavailability. Inactivation of enteric CYP3A4 was probably not involved. Naringin appears to have sufficient safety, specificity, and sensitivity to be a clinical OATP1A2 inhibitor probe. Inherent OATP1A2 activity may be influenced by genetic factors. This appears to be the first report of a single dietary constituent clinically modulating drug transport.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kelder, J., Grootenhuis, P. D. J., Bayada, D. M., Delbressine, L. P. C., & Ploemen, J.-P. (1999) · Pharmaceutical Research · doi:10.1023/a:1015040217741 · Cited by 813
Lown, K. S., Bailey, D. G., Fontana, R. J., Janardan, S. K., Adair, C. H., Fortlage, L. A., Brown, M. B., Guo, W., & Watkins, P. B. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119439 · Cited by 624
Self-citationHo, R. H., Tirona, R. G., Leake, B. F., Glaeser, H., Lee, W., Lemke, C. J., Wang, Y., & Kim, R. B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.034 · Cited by 611
Self-citationDresser, G. K., Bailey, D. G., Leake, B. F., Schwarz, U. I., Dawson, P. A., Freeman, D. J., & Kim, R. B. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121152 · Cited by 606
Self-citationOATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine
Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., & Kim, R. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15235-x · Cited by 597
Self-citationTransporters and drug therapy: Implications for drug disposition and disease
HO, R., & KIM, R. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.011 · Cited by 502
Self-citationWiniwarter, S., Bonham, N. M., Ax, F., Hallberg, A., Lennernäs, H., & Karlén, A. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9810102 · Cited by 453
Kobayashi, D., Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051300 · Cited by 416
Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans
Glaeser, H., Bailey, D. G., Dresser, G. K., Gregor, J. C., Schwarz, U. I., McGrath, J. S., Jolicoeur, E., Lee, W., Leake, B. F., Tirona, R. G., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100056 · Cited by 407
Self-citationPolymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2)
Lee, W., Glaeser, H., Smith, L. H., Roberts, R. L., Moeckel, G. W., Gervasini, G., Leake, B. F., & Kim, R. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411092200 · Cited by 365
Self-citationFunctional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human
Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060194 · Cited by 351
Hollenberg, P. F., Edwards, D. J., He, K., Fitzsimmons, M. E., Fisher, J. M., Rahman, A., Thummel, K. E., Lown, K. S., Woster, P. M., Schmiedlin‐Ren, P., et al. (2019) · PubMed · doi:10.17615/k2j5-jx75 · Cited by 349
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
He, K., Iyer, K. R., Hayes, R. N., Sinz, M., Woolf, T. F., & Hollenberg, P. F. (1998) · Chemical Research in Toxicology · doi:10.1021/tx970192k · Cited by 312
Flavanone absorption after naringin, hesperidin, and citrus administration*
Ameer, B., Weintraub, R. A., Johnson, J. V., Yost, R. A., & Rouseff, R. L. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90164-2 · Cited by 300
The fate of naringin in humans: A key to grapefruit juice-drug interactions?
Fuhr, U., & Kummert, A. L. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90048-9 · Cited by 252
Peter, F., & Kim, D.-H. (1990) · Carcinogenesis · doi:10.1093/carcin/11.12.2275 · Cited by 245
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin
LILJA, J., KIVISTO, K., & NEUVONEN, P. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)90048-6 · Cited by 241
Grapefruit juice–felodipine interaction: Mechanism, predictability, and effect of naringin
Bailey, D. G., Arnold, J. M. O., Munoz, C., & Spence, J. D. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.84 · Cited by 230
Self-citationInhibition Selectivity of Grapefruit Juice Components on Human Cytochromes P450
Tassaneeyakul, W., Guo, L.-Q., Fukuda, K., Ohta, T., & Yamazoe, Y. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1835 · Cited by 229
CITRUS JUICES INHIBIT THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B
Satoh, H., Yamashita, F., Tsujimoto, M., Murakami, H., Koyabu, N., Ohtani, H., & Sawada, Y. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002337 · Cited by 225
Identification of 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice.
Edwards, D. J., Bellevue, F. H., & Woster, P. M. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08464-8 · Cited by 217
Malhotra, S. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113185 · Cited by 207
Organic anion‐transporting polypeptide (OATP) transporter family and drug disposition
Kim, R. B. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.33.s2.5.x · Cited by 200
Self-citationGrapefruit Juice Activates P-Glycoprotein-Mediated Drug Transport
Soldner, A., Christians, U., Susanto, M., Wacher, V. J., Silverman, J. A., & Benet, L. Z. (1999) · Pharmaceutical Research · doi:10.1023/a:1011902625609 · Cited by 193
Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics
Bailey, D. G., Arnold, J. M. O., Strong, H. A., Munoz, C., & Spence, J. D. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.195 · Cited by 188
Self-citationTime course of recovery of cytochrome p450 3A function after single doses of grapefruit juice
Greenblatt, D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00118-8 · Cited by 188
Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin
Lilja, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110216 · Cited by 187
Dresser, G. K., Kim, R. B., & Bailey, D. G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.10.005 · Cited by 186
Self-citationShimizu, M., Fuse, K., Okudaira, K., Nishigaki, R., Maeda, K., Kusuhara, H., & Sugiyama, Y. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004622 · Cited by 183
Paine, M. F., Widmer, W. W., Hart, H. L., Pusek, S. N., Beavers, K. L., Criss, A. B., Brown, S. S., Thomas, B. F., & Watkins, P. B. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.5.1097 · Cited by 160
Ohnishi, A., Matsuo, H., Yamada, S., Takanaga, H., Morimoto, S., Shoyama, Y., Ohtani, H., & Sawada, Y. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703433 · Cited by 158
Lundahl, J., Reg�rdh, C. G., Edgar, B., & Johnsson, G. (1995) · European Journal of Clinical Pharmacology · doi:10.1007/bf00192360 · Cited by 141
Takanaga, H., OHNISHI, A., MURAKAMI, H., Matsuo, H., Higuchi, S., Urae, A., Irie, S., Furuie, H., 松隈京子, & KIMURA, M. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.104215 · Cited by 131
Transport Characteristics of Fexofenadine in the Caco-2 Cell Model
Petri, N., Tannergren, C., Rungstad, D., & Lennernäs, H. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000036913.90332.b1 · Cited by 130
Pharmacogenomics of the OATP and OAT Families
Marzolini, C., Tirona, R. G., & Kim, R. B. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.3.273.29831 · Cited by 124
Self-citationPharmacogenomics of organic anion-transporting polypeptides (OATP)
Tirona, R. G., & Kim, R. B. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00077-7 · Cited by 112
Self-citationBailey, D. G., Kreeft, J. H., Munoz, C., Freeman, D. J., & Bend, J. R. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90173-4 · Cited by 108
Self-citationTransporters and Drug Discovery: Why, When, and How
Kim, R. B. (2006) · Molecular Pharmaceutics · doi:10.1021/mp050084o · Cited by 89
Self-citationDihydroxybergamottin Caproate as a Potent and Stable CYP3A4 Inhibitor
Ohta, T., Nagahashi, M., Hosoi, S., & Tsukamoto, S. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00362-5 · Cited by 29
Cited by
Impact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation
Klaassen, C. D., & Aleksunes, L. M. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002014 · Cited by 807
Alam, M. A., Subhan, N., Rahman, M. M., Uddin, S. J., Reza, H. M., & Sarker, S. D. (2014) · Advances in Nutrition · doi:10.3945/an.113.005603 · Cited by 788
Roth, M., Obaidat, A., & Hagenbuch, B. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01724.x · Cited by 767
Coexistence of passive and carrier-mediated processes in drug transport
Sugano, K., Kansy, M., Artursson, P., Avdeef, A., Bendels, S., Di, L., Ecker, G. F., Faller, B., Fischer, H., Gerebtzoff, G., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3187 · Cited by 649
Metadata
- Authors
- Bailey, D. G., Dresser, G. K., Leake, B. F., & Kim, R. B.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-02-14
- Volume
- 81
- Issue
- 4
- Pages
- 495-502
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2134431157
- Cited by
- 287
- References
- 39
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.